INKT News and Press, MiNK Therapeutics Inc. From 11/10/22

Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a reduction of target and non-target lesions or disease stabilization First immune cell...

MiNK Therapeutics, Inc. (INKT) Q3 2022 Earnings Conference Call November 2, 2022 Company Participants Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily ...

MiNK Therapeutics press release ( NASDAQ: INKT ): Q3 GAAP EPS of $0.19. We ended the third quarter 2022 with a cash balance of $24.2 million as compared to $38.9 million at December 31, 2021. For further details see: MiNK Therapeutics GAAP EPS of $0.19

-  Five presentations on clinical data and novel pipeline candidates at the Society of Cancer Immunotherapy (SITC) Meeting -  R&D Day on November 10, 2022, from 4:00-6:00pm ET in Boston and via webcast NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeuti...

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-m...

Experts in disease pathways discuss clinical data of allo-iNKTs R&D strategy driving pipeline momentum, productivity, and innovation Internal scalable manufacturing of fully allogeneic iNKT cells; expanded capacity to ~700,000 doses R&D event: November 10...

Clinical data on AgenT-797, allogeneic (allo) iNKTs, +/- anti-PD-1 in advanced solid tumors Clinical data of AgenT-797 in viral ARDS and refractory multiple myeloma New therapeutic candidates: 1) MiNK-215, an allo-FAP-CAR-iNKT; 2) MiNK-413, allo- armored -BCMA-CAR-iNKT ...

NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-m...

Gainers: Curis ( CRIS ) +36% . Allarity Therapeutics ( ALLR ) +23% . Codiak BioSciences ( CDAK ) +21% . Cassava Sciences ( SAVA ) +17% .  AlerisLife ( ALR ) +11% . Losers: Blue Water Vaccines ( BWV ) -27% ...

Gainers: Blue Water Vaccines ( BWV ) +57% . Eargo ( EAR ) +49% . Cassava Sciences ( SAVA ) +29% . MiNK Therapeutics ( INKT ) +24% . Cogent Biosciences ( COGT ) +16% . Losers: Blueprint Medicines ( BPMC ) -22% ....